53 results
424B5
VRDN
Viridian Therapeutics Inc
19 Jan 24
Prospectus supplement for primary offering
4:32pm
significant medical benefit for patients. We are engineering medicines to address unmet medical needs for patients and further advance drug innovation
424B5
VRDN
Viridian Therapeutics Inc
17 Jan 24
Prospectus supplement for primary offering
4:04pm
medical benefit for patients. We are engineering medicines to address unmet medical needs for patients and further advance drug innovation.
Recent
S-3ASR
VRDN
Viridian Therapeutics Inc
30 Nov 23
Automatic shelf registration
4:05pm
significant medical benefit for patients. We are engineering medicines to address unmet medical needs for patients and further advance drug innovation … held in the aggregate by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., and RTW Biotech Opportunities Ltd (collectively, the “RTW Funds
8-K
EX-10.1
jhy7v7 ww69p0m6
30 Oct 23
Entry into a Material Definitive Agreement
8:35am
8-K
EX-10.2
0y8g4bnya5r3qve1d7iz
30 Oct 23
Entry into a Material Definitive Agreement
8:35am
S-3ASR
5st5 r3g1
24 Jul 23
Automatic shelf registration
4:06pm
8-K
EX-99.1
sv6xdy 8247mmz0lzb
10 Mar 22
Viridian Therapeutics Reports Fourth Quarter and Full Year 2021
4:16pm
8-K
EX-99.1
zaf7v6jpxu3s7pqp7uu
25 Mar 21
Viridian Therapeutics Reports 2020 Financial Results and Provides Corporate Updates
4:06pm